Connect with us

Politics

Oregon Psilocybin Panel Teams Up With Harvard To Research Psychedelic History And Impacts Of Reform

Published

on

An Oregon state panel charged with advising on the implementation of a legal psilocybin therapy program has cleared a team of researchers to produce a comprehensive report on the science, history and culture of the psychedelic as regulators prepare to license facilities to administer it.

Members of the Oregon Psilocybin Advisory Board released an initial report in July that reviewed hundreds of studies into psilocybin, as required under the state’s historic, voter-approved 2020 medical legalization initiative. But they were pressed for time and will now be working with a recently established psychedelic research center at Harvard Law School to more thoroughly cover the subject.

Part of the intent of the new expanded research project is to help inform legislative efforts outside of Oregon where psychedelics reform is being considered.

“Given increasing interest in psychedelics legislation, Oregon will likely be the first of several states to contemplate regulating psilocybin services,” Mason Marks, who serves on the Oregon advisory board for psilocybin, told Marijuana Moment.

“To the extent that the [Ethical, Legal, and Social Implications] Report can help inform their decision making, it should be made available for that purpose,” Marks, who is also the director of Harvard’s first-of-its-kind psychedelics policy center, said. “Hopefully, it can provide a bit of a roadmap for fruitful collaboration between states and the federal government.”

The initial report that Oregon’s review panel submitted did conclude that psilocybin holds significant medical value for a number of mental health conditions. The substance is shown to be “efficacious in reducing depression and anxiety, including in life-threatening conditions,” members found.

But this forthcoming second review—which the board approved late last month and will take up to six months to complete—will cover much more ground. For example, experts will look at how psilocybin prohibition has “affected marginalized communities” and how Oregon’s reform law could impact those individuals.

Any recommendations included in the report will still need approval by the full board before being submitted to regulators at the Oregon Health Authority for consideration.

“Potential sources of data include historical information on the Indigenous use of psilocybin, anthropology literature, religious scholarship, bioethics literature, medical and psychological literature from the mid-twentieth century, narrative descriptions of psilocybin use, public health data, legislative materials, and legal scholarship,” a research proposal states. “The project will review and analyze existing research only.”

Marks told Marijuana Moment that it’s “important to include the views and practices of Indigenous communities because their technologies are the foundation of the psychedelics industry.”

“Some cultures have used psychedelics including psilocybin for hundreds or thousands of years. In many respects, they are the authorities in this space, and we should acknowledge and respect their expertise,” he said. “There is often a tendency to take from marginalized communities or adopt policies without concern for how they are affected.”

“Marginalized communities should also be included because the U.S. war on drugs has had a devastating impact on them. Decades of punitive drug enforcement policies have disproportionately impacted communities of color, torn families apart, and destroyed many lives through violence and incarceration. Meanwhile, prohibition has deprived people with mental health conditions, another marginalized community, of the potential benefits of psilocybin. Its status as a Schedule I controlled substances inhibited research for half a century.”

Other topics that the report will cover include how psilocybin affects communities, how cultural attitudes toward the psychedelic have changed over time, what community-based rituals have been established around psilocybin, how the entheogen could impact addiction and overdose rates and how other jurisdictions have reformed laws governing psilocybin.

“The ELSI Report picks up where the Rapid Evidence Review left off. Without the time constraints of the first report, it can take a broader, more inclusive approach,” Marks said. “Some sources of particular importance may include academic literature from the fields of anthropology, law, public health, psychology, religion, and sociology.”

Oregon Gov. Kate Brown’s (D) office announced the appointment of 17 members of the psilocybin advisory board in March. The panel is meant to help facilitate the implementation of the historic reform initiative.

The developments in Oregon come as lawmakers and advocates across the U.S. continue to pursue psychedelics reform.

Michigan senators on Thursday introduced a bill to legalize the possession, cultivation and delivery of an array of plant- and fungus-derived psychedelics like psilocybin and mescaline.

The Ann Arbor, Michigan City Council approved entheogenic decriminalization last year—and in July, local lawmakers passed a resolution to officially designate September as Entheogenic Plants and Fungi Awareness Month.

Efforts are also underway in Grand Rapids to enact a policy change for the psychedelic substances.

A California senator advanced a bill to legalize the possession of psychedelics through the Senate and two Assembly committees, but he recently put the effort on pause until next year to generate additional buy-in.

Activists in California are also hoping to place an initiative before voters in 2022 to legalize the possession and sale of psilocybin. And a legislative analysis of the proposal that was released last week found that it would reduce costs associated with enforcing laws against the substance.

Oakland and Santa Cruz have already enacted psychedelics decriminalization.

Meanwhile, Denver activists who successfully led a 2019 campaign to make the city the first in the U.S. to decriminalize psilocybin possession have their eyes set on broader reform, with plans in the works to end the criminalization of noncommercial gifting and communal use of the psychedelic.

Massachusetts cities that have enacted the policy change are: Northampton, Somerville and Cambridge. In July, state lawmakers heard testimony about a bill to create a task force charged with studying the implications of legalizing psychedelics like psilocybin and ayahuasca.

The governor of Connecticut recently signed legislation recently that includes language requiring the state to carry out a study into the therapeutic potential of psilocybin mushrooms.

Texas also recently enacted a bill to require the state study the medical benefits of psychedelics for military veterans.

A New York lawmaker introduced a bill in June that would require the state to establish an institute to similarly research the medical value of psychedelics.

In Oakland, the first city where a city council voted to broadly deprioritize criminalization of entheogenic substances, lawmakers approved a follow-up resolution in December that calls for the policy change to be adopted statewide and for local jurisdictions to be allowed to permit healing ceremonies where people could use psychedelics.

After Ann Arbor legislators passed a decriminalization resolution last year, a county prosecutor announced that his office will not be pursuing charges over possessing entheogenic plants and fungi—“regardless of the amount at issue.”

The Aspen, Colorado City Council discussed the therapeutic potential of psychedelics like psilocybin and proposals to decriminalize such substances at a meeting in May. But members said, as it stands, enacting a reform would be more better handled at the state level while entheogens remain strictly federally controlled.

Seattle lawmakers also recently sent a letter to members of a local task force focused on the opioid overdose epidemic, imploring the group to investigate the therapeutic potential of psychedelics like ayahuasca and ibogaine in curbing addiction. In response, the task force issued a recommendation for the widespread decriminalization of all drugs. The group said psychedelics in particular could represent a promising treatment to address substance abuse disorders and mental health issues.

Meanwhile, Portland, Oregon activists are mounting a push to have local lawmakers pass a resolution decriminalizing the cultivation, gifting and ceremonial use of a wide range of psychedelics.

In a setback for advocates, the U.S. House of Representatives recently voted against a proposal from Rep. Alexandria Ocasio-Cortez (D-NY) that would have removed a spending bill rider that advocates say has restricted federal funds for research into Schedule I drugs, including psychedelics such as psilocybin, MDMA and ibogaine. However, it picked up considerably more votes this round than when the congresswoman first introduced it in 2019.

Report provisions of separate, House-passed spending legislation also touch on the need to expand cannabis and psychedelics research. The panel urged the National Institute On Drug Abuse (NIDA) to support expanded marijuana studies, for example. It further says that federal health agencies should pursue research into the therapeutic potential of psychedelics for military veterans suffering from a host of mental health conditions.

When it comes to broader drug policy reform, Oregon voters also approved an initiative in November to decriminalize possession of all drugs. This year, the Maine House of Representatives passed a drug decriminalization bill, but it later died in the Senate.

In May, lawmakers in Congress filed the first-ever legislation to federally decriminalize possession of illicit substances.

Read the advisory board’s proposal on the broader psilocybin report below: 

Psilocybin research proposa… by Marijuana Moment

Biden’s Drug Czar Wants To Make It Easier To Research Marijuana, Psychedelics And Other Schedule I Substances

Image courtesy of Kristie Gianopulos.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Politics

Wisconsin Republicans Announce Limited Medical Marijuana Legalization Bill

Published

on

More than a dozen Republican Wisconsin lawmakers announced on Wednesday that they are filing a bill to legalize medical marijuana in the state.

Sen. Mary Felzkowski (R) and Rep. Patrick Snyder (R) are leading the bicameral effort, though advocates are already skeptical considering how the GOP-legislature has historically resisted and blocked cannabis reform. On Tuesday, for example, the Senate passed a bill to increase penalties for people who use butane to extract marijuana resin, and GOP members also shot down an amendment to the measure that would have legalized adult-use cannabis.

The Republican-led medical cannabis legislation is also fairly restrictive, as it prohibits smokable marijuana products and doesn’t allow patients to grow cannabis for personal use. Patients could only obtain cannabis preparations in the form of oils, pills, tinctures or topicals.

What it would do is allow doctors to issue medical cannabis recommendations to patients with one of eight conditions, including cancer, seizure disorders, post-traumatic stress disorder and multiple sclerosis.

Assembly Speaker Robin Vos has expressed support for medical cannabis reform, and the lead Senate sponsor said at Wednesday’s press conference that Majority Leader Devin LeMahieu (R) is “more than willing” to hold a hearing on the proposal.

Under the bill, a medical marijuana regulatory commission would be established through the Department of Revenue to promulgate rules for the program in consultation with a medical cannabis advisory board. The commission could add more qualifying conditions.

Licensed processors would be taxed at a rate of 10 percent for “each wholesale sale in this state of medical marijuana to a licensed dispensary,” the text of the bill says. Revenue would go toward a medical marijuana fund to support drug prevention and treatment programs.


Marijuana Moment is already tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

It does not appear that the measure contains equity provisions like expungements that are favored by progressives.

“Currently 36 other states, including our neighbors Michigan, Illinois, and Minnesota, have passed laws allowing patients with certain medical conditions to access medical marijuana if their doctors recommend it,” a co-sponsorship memo that Felzkowski and Snyder sent to fellow legislators on Wednesday says. “Medicine is never one-size-fits-all, and it is time for Wisconsin to join the majority of the country in adding another option which may help patients find the relief they need.”

The memo also discusses how voters in multiple cities and counties across Wisconsin have strongly approved local, non-binding ballot referendums expressing support for marijuana reform in recent years.

“Wisconsinites who have discussed the positive benefits of using marijuana for medicinal purposes with their primary care physicians are currently forced to endure pain and physical agony, traffic drugs into Wisconsin and become criminals, or be held hostage by the FDA approved pain killers that may alleviate their pain, but come with a host of side effects that diminish quality of life,” a summary of the proposal says.

This isn’t the only cannabis bill that’s up for consideration in the Wisconsin legislature.

In November, a bipartisan pair of legislators introduced a bill to decriminalize low-level marijuana possession. In August, three senators separately filed legislation to legalize cannabis for adult use in the state.

As it stands, marijuana possession is punishable by a maximum $1,000 fine and up to six months in jail for a first offense. People convicted of a subsequent offense would face a felony charge punishable by a maximum $10,000 fine and up to three and a half years in prison.

Gov. Tony Evers (D) tried to legalize recreational and medical marijuana through his proposed state budget last year, but a GOP-led legislative committee stripped the cannabis language from the legislation. Democrats tried to add the provisions back through an amendment the next month, but Republicans blocked the move.

Other Republican lawmakers have filed bills to more modestly decriminalize marijuana possession in the state, but none of those proposals advanced during last year’s session.

Evers held a virtual town hall event last year where he discussed his cannabis proposal, emphasizing that polling demonstrates that Wisconsin residents back the policy change.

And in the interim as lawmakers pursue reform, the governor has issued more than 300 pardons during his years in office, primarily to people convicted of non-violent marijuana or other drug offenses.

Colorado Activists File Revised Ballot Initiatives To Legalize Psilocybin And Establish ‘Healing Centers’

Photo courtesy of Chris Wallis // Side Pocket Images.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Delaware Lawmakers Approve Marijuana Legalization Bill In Committee Vote

Published

on

A bill to legalize marijuana in Delaware cleared its first legislative hurdle on Wednesday, advancing out of the House Health and Human Development Committee on a 10-4 vote.

The legislation is sponsored by Rep. Ed Osienski (D), who introduced a similar proposal last year. The Health and Human Development Committee approved last year’s measure, too, but it ultimately stalled ahead of an expected floor vote due to disagreements over social equity provisions. At the time, Osienski pledged to bring a revised bill for the 2022 session that could earn broad enough support to pass.

Osienski said at the hearing that the proposal would “create good-paying jobs for Delawareans while striking a blow against the criminal element which profits from the thriving illegal market in our state.”

Rep. Paul Baumbach (D), a cosponsor of both the current and past versions of the legalization bill, thanked Osienski for his efforts to tweak and strengthen the bill over time.

“You’ve listened so much to so many concerns,” he said, “and you and the staff have incorporated so many of the best ideas there are for this matter.”

One of the few vocal opponents to the bill at Wednesday’s hearing was Rep. Charles S. Postles Jr. (R), who said he didn’t “believe in either extreme, that of legalization or of excessive punitiveness” and worried that legalization would send a message to kids that cannabis use is safe. “We’re talking about the government telling our young people, ‘This stuff is fine. Go do it.'”

The bill, HB 305, would allow adults 21 and older to purchase and possess up to one ounce of cannabis, including up to five grams of cannabis concentrates. Growing marijuana at home, as well as home delivery by licensed businesses, would be prohibited.

A marijuana commissioner under the state Division of Alcohol and Tobacco Enforcement would regulate the industry and oversee licensing of retailers, cultivators, manufacturers and laboratories. Licenses would be granted through a scored, competitive process, with advantages given to those who pay workers a living wage, provide health insurance or meet certain other benchmarks.


Marijuana Moment is already tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

Efforts at social equity are built into the licensing scheme. After 19 months of the bill’s enactment, for example, regulators would have to approve 30 retailer licenses, half of which would go to social equity applicants. Social equity applicants—defined as entities majority-owned by people with past cannabis convictions or who live in an area disproportionately impacted by the drug war—would also be allotted one-third of the planned 60 cultivation licenses, one-third of manufacturing licenses and two of five licenses for testing laboratories.

Equity applicants would also qualify for reduced application and licensing fees as well as technical assistance from the state.

Retail sales of cannabis would be subject to a 15 percent excise tax, which would not be applied to medical marijuana products.

Of the tax revenue, 7 percent would go to a new Justice Reinvestment Fund, which would support grants, services and other initiatives that focus on issues such as jail diversion, workforce development and technical assistance for people in communities that are economically disadvantaged and disproportionately impacted by the drug war. The money would also be used to help facilitate expungements, according to a summary from the advocacy group Marijuana Policy Project (MPP).

When Osienski’s earlier bill was being considered last year, a similar equity fund provision was included, and the sponsor said he was caught off guard when he was informed that its inclusion meant the bill would require 75 percent of legislators in the chamber to approve it.

Osienski attempted to address the problem through an amendment, but some members of the Black Caucus opposed the changes, and the measure failed.

The current bill will still require a supermajority threshold to pass, but a smaller one of 60 percent.

Osienski has worked with the Black Caucus in the ensuing months to build support and move toward more passable legislation. And a clear sign of the progress is that Reps. Rae Moore (D) and Nnamdi Chukwuocha (D) have already signed on as cosponsors to the new bill after pulling their support for the 2021 version over equity concerns.

Chukwoucha said at Wednesday’s hearing that he believed past versions of the bill fell short on addressing past injustice against people of color. The current version, he said, does better.

“We spoke about the harms in communities and [how] individuals who look like me are four times more likely to be arrested for marijuana offenses, but we didn’t really see redress in the bill,” Chukwoucha said. He thanked Osienski for working with stakeholders to address those concerns.

In 2019, Osienski was the chief sponsor of a legalization bill that cleared a House committee but did not advance through the full chamber. That bill would have allowed medical cannabis dispensaries to begin selling marijuana to adults 21 and older while the rest of the adult-use industry was still preparing to launch, a provision that was removed from later versions.

Four of the state’s six medical marijuana companies came out publicly against that change and testified in opposition to last year’s bill. In response, Delaware activists mounted a boycott against those operators.

During public testimony on Wednesday, a representative from a subsidiary of one multi-state dispensary operator, Columbia Care, said the group supports the bill.

Representatives from various state agencies, meanwhile, raised worries about some of the bill’s provisions and encouraged changes to the plan. The Department of Health and Social Services, for example, urged investment in substance use disorder treatment programs and public awareness campaigns about the risks of cannabis use. A Department of Agriculture representative called for outdoor cannabis cultivation to be forbidden, among other changes.

The Department of Finance, meanwhile, said that while the bill addressed some of the department’s past concerns, it would nevertheless create problems for administrators handling tax collection and other transactions, especially because much of the cannabis industry relies on cash.

Osienski said at the beginning of the hearing that he was expecting the agency pushback after Gov. John Carney’s (D) office sent him a list of concerns on Tuesday afternoon. “I want to reassure you that we have met in the past with these agencies,” he said, “and we will continue to meet with them to address these concerns.”

Advocates cheered the decision to advance the bill.

“The House Human Development committee’s approval of HB 305 today is the first step towards bringing equitable legalization to the state this year,” Olivia Naugle, senior policy analyst for Marijuana Policy Project, told Marijuana Moment on Wednesday. “Delaware has the opportunity to join 18 other states and DC that have legalized cannabis for adults—including their neighbor, New Jersey. It is past time for the legislature to listen to their constituents and meet the moment.”

Several modest amendments that were filed when last year’s bill was being considered have been incorporated into the new measure. Those include provisions related to quality control standardization, accreditation for marijuana testing facilities and packaging and labeling requirements.

Portions of the bill on expungements were also removed, as they were made redundant by the enactment of separate legislation last year.

Individual municipalities would be able to establish their own regulations for marijuana business operating times and locations, and they would also be able to ban cannabis companies altogether from their jurisdiction.

As supportive lawmakers work to push the bill through the legislature, they also face the challenge of winning over Carney, one of the rare Democratic governors who remain opposed to legalization.

Despite his wariness about adult-use legalization, Carney did sign two pieces of marijuana expungement legislation in recent years. In 2017 and 2018, a state task force met to discuss issues related to legalization, and the governor hosted a series of roundtable meetings about cannabis.

A legalization bill previously received majority support on the House floor in 2018, but it failed to receive the supermajority needed to pass.

Carney’s predecessor approved a measure to decriminalize simple possession of cannabis in 2015.

An analysis from State Auditor Kathy McGuiness (D) released last year found that Delaware could generate upwards of $43 million annually in revenue from regulating marijuana and imposing a 20 percent excise tax. The legal market could also create more than 1,000 new jobs over five years if the policy is enacted, according to the report.

Amazon Endorses GOP-Led Bill To Federally Legalize Marijuana

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Colorado Activists File Revised Ballot Initiatives To Legalize Psilocybin And Establish ‘Healing Centers’

Published

on

Colorado activists have filed revised versions of a pair of 2022 ballot initiatives to legalize psilocybin and create licensed “healing centers” where people can use the psychedelic for therapeutic purposes. The move comes as state lawmakers have introduced a separate bill to require a study into the efficacy of plant-based psychedelics.

The ballot measures—filed by Kevin Matthews, the campaign manager behind Denver’s historic 2019 vote to locally decriminalize psilocybin and entrepreneur Veronica Perez—are similar to earlier versions the advocates filed with the secretary of state’s office last month, with a few key changes concerning the rollout of the reform, promoting equity and possession limits.

For the original initiatives, the campaign was considering two options: one would have legalized a wide range of entheogenic substances including DMT, ibogaine and mescaline, as well as establish a regulatory model for psychedelics therapy. The other would have initially enacted the reform for psilocybin and psilocin alone.

But recognizing that regulators would be faced with an onerous task to set up rules for multiple psychedelics, activists decided to take a different approach with the new measures. For both, there would be a two-tiered regulatory model, where only psilocybin would be legalized and regulated for therapeutic use until June 2026, after which point regulators could expand the policy change to include other psychedelics that are listed in the proposal.

“We really wanted to make sure that the administration had time to set up a proper regulatory structure—first for psilocybin and then for any further natural medicines,” Rick Ridder of RBI Strategies, a spokesperson for the campaign, told Marijuana Moment on Monday.

The decision to add additional psychedelics to the program would be made by the Department of Regulatory Agencies in consultation with a Natural Medicine Advisory Board that would be established. The board would be comprised of 15 members, including people who have experience with psychedelic medicine in a scientific and religious context.

Another major change from the prior versions is that the revised initiatives do not contain explicit “allowable” possession limits—a provision that had garnered pushback from certain Colorado activists when the original measures were filed.

And unlike the last two versions of the initiatives, these new measures also include specific provisions meant to “ensure the regulatory access program is equitable and inclusive and to promote the licensing of and the provision of natural medicine services” for people who have been disproportionately impacted by drug criminalization, who face challenges accessing health care, have “traditional or indigenous history with natural medicines” and military veterans.

Those rules could involve, but are not limited to, reduced licensing fees, reduced costs for low-income people and an annual review of “the effectiveness of such policies and programs.”

“I think what this is is a giant step forward for mental health treatment in the state of Colorado,” Ridder said. “As we’ve looked at the results of research throughout the world, we’re seeing very promising data related to particularly healthy people with PTSD, with suicidal tendencies and end-of-life. And this is just an opportunity to bring that kind of natural medicine and medicinal help to citizens here in Colorado.”

The two new initiatives are nearly identical to each other, except that one contains a component specifically authorizing people to petition courts for record sealing for past convictions that would be made legal under the proposal.

Under the proposals, the Department of Regulatory Agencies would be responsible for developing rules for a therapeutic psychedelics program where adults 21 and older could visit a licensed “healing center” to receive treatment under the guidance of a trained facilitator.

This latest filing comes more than two years after Denver became the first city in the U.S. to decriminalize psilocybin mushrooms. Various activists, including those involved in the 2019 campaign, have signaled interest in building upon the reform.

The initiatives must still be assigned an official ballot title and summary from the state before they’re approved to begin signature gathering. The measures are scheduled to receive a review and comment hearing on February 3. If approved by state officials, activists will choose one of the measures to pursue and will then need to collect 124,632 valid signatures from registered voters to achieve ballot access.

The Colorado ballot initiatives seek to accomplish something similar to what California activists are actively pursuing. California advocates are in the process of collecting signatures for a ballot initiative to legalize psilocybin mushrooms in the state.

Meanwhile, in Colorado, Sen. Joann Ginal (D) and Rep. Alex Valdez (D) filed a modest bill last week to create a one-year plant-based medicine policy review panel that would be tasked with studying the “use of plant-based medicines to support mental health,” according to a summary. The ballot campaign is not affiliated with that legislative effort.


Marijuana Moment is already tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

“The policy review panel shall submit a report on its findings and policy recommendations to the House of Representatives Public and Behavioral Health and Human Services Committee and the Senate Health and Human Services Committee, or any successor committees; the governor; and the Department of Human Services,” it says.

Meanwhile, legislative efforts to enact psychedelics reform are also underway in other states across the country.

For example, a bill to decriminalize a wide array of psychedelics in Virginia was taken up by a House of Delegates panel on Monday, only to be pushed off until 2023. But there’s still a separate but similar reform proposal that’s pending in the Senate.

Two Republican Oklahoma lawmakers recently filed bills meant to promote research into the therapeutic potential of psilocybin, and one of the measures would further decriminalize low-level possession of the psychedelic.

A GOP Utah lawmaker also introduced a bill last week that would set up a task force to study and make recommendations on the therapeutic potential of psychedelic drugs and possible regulations for their lawful use.

In Kansas, A lawmaker also recently filed a bill to legalize the low-level possession and cultivation of psilocybin mushrooms.

A Republican Missouri lawmaker introduced a bill this month to give residents with serious illnesses legal access to a range of psychedelic drugs like psilocybin, ibogaine and LSD  through an expanded version of the state’s existing right-to-try law.

California Sen. Scott Wiener (D) told Marijuana Moment in a recent interview that his bill to legalize psychedelics possession stands a 50/50 chance of reaching the governor’s desk this year. It already cleared the full Senate and two Assembly committees during the first half of the two-year session.

In Michigan, a pair of state senators introduced a bill in September to legalize the possession, cultivation and delivery of various plant- and fungi-derived psychedelics like psilocybin and mescaline.

Washington State lawmakers also introduced legislation this month that would legalize what the bill calls “supported psilocybin experiences” by adults 21 and older.

In Vermont, a broad coalition of lawmakers representing nearly a third of the House introduced a bill to decriminalize drug possession.

New Hampshire lawmakers filed measures to decriminalize psilocybin and all drugs.

Last year, the governor of Connecticut signed legislation that includes language requiring the state to carry out a study into the therapeutic potential of psilocybin mushrooms.

At the congressional level, bipartisan lawmakers sent a letter to the Drug Enforcement Administration (DEA) this month, urging that the agency allow terminally ill patients to use psilocybin as an investigational treatment without the fear of federal prosecution.

Virginia House Committee Pushes Back Psychedelics Decriminalization Bill Until 2023, But Senate Proposal Still Pending

Photo courtesy of Dick Culbert.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Marijuana Moment